Skip to main content

Market Overview

Recap: Amicus Therapeutics Q2 Earnings

Share:

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).

Revenue of $62,353,000 rose by 41.29% from the same period last year, which missed the estimate of $62,380,000.

Outlook

The upcoming fiscal year's revenue expected to be between $250,000,000 and $260,000,000.

Conference Call Details

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/fvhk9nzf

Price Action

Company's 52-week high was at $16.13

Company's 52-week low was at $6.25

Price action over last quarter: Up 32.05%

Company Profile

Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.

 

Related Articles (FOLD)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com